Cancer Research UK logo.
SearchDonate
  • Search

A trial looking at ibrutinib with and without treatment breaks for chronic lymphocytic leukaemia (STATIC)

Overview

Cancer types:

Blood cancers, Chronic leukaemia, Chronic lymphocytic leukaemia (CLL), Leukaemia, Low grade lymphoma, Lymphoma, Non-Hodgkin lymphoma (NHL)

Status:

Open

Phase:

Phase 3

Details

This trial is comparing the targeted cancer drug ibrutinib with, and without, treatment breaks. It is for people with either:

  • chronic lymphocytic leukaemia (CLL)

  • small lymphocytic lymphoma (SLL)

It is for people who have already taken ibrutinib either:

  • in the FLAIR trial or

  • on the NHS because their CLL or SLL did not go away with their first treatment or it has come back

Recruitment start: 29 September 2022

Recruitment end: 31 March 2028

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Dr Talha Munir

Supported by

University of Leeds

University of Leeds Clinical Trials Research Unit

National Institute of Health Research (NIHR) Health Technology Assessment (HTA) Programme

Janssen Pharmaceutica NV

Last reviewed: 20 February 2025

CRUK internal database number: 19863

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and support

An icon of a hand shake.

Questions for your doctor

What to ask your doctor about clinical trials.

An icon of two speech bubbles, indicating a conversation.

Cancer chat forum

Meet and chat to other cancer people affected by cancer.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.